Contents

1 Performance Highlights and Financial Review

2 Strengths and Key Growth Drivers

3 Pharmaceutical

4 Med Tech

5 Healthcare Services

6 Appendix

Performance Highlights and Financial Review

Performance Highlights (1/2)

Launched Product

Serplulimab Injection (PD-1)

- 2023Q1 revenue RMB250 million
- Approved for MSI-H, sqNSCLC, ES-SCLC in Chinese Mainland
- SCLC was granted with Orphan -drug Designation from FDA and EC
- The MAA of ES-SCLC was accepted by the EMA

Trastuzumab Injection (HER2)

- 2023Q1 domestic sales RMB540 million (+66.7% YoY)
- The BLA for breast cancer and metastatic gastric cancer indications was accepted by the FDA

Keverprazan Hydrochloride

- Launched in Chinese Mainland for the treatment of duodenal ulcer (DU) and reflux esophagitis (RE)

Product Pipeline

- FS-1502 HER2-ADC for HER2-positive locally advanced or metastatic breast cancer initiated Ph3 clinical trial in Chinese Mainland
- FCN-159 (MEK small molecule * for histiocytic tumors, HLX208 (BRAF V600E Inhibitor) * for adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) with BRAF V600E mutation have been granted with the Breakthrough Therapy Designation by the NMPA
- Completed the enrollment of the Ph3 clinical trial of 13-valent pneumococcal conjugate vaccines (multivalent combinations) * in Chinese Mainland
- The BLA of RT002 (DaxibotulinumtoxinA) *for the temporary improvement of moderate to severe glabellar lines in adults caused by corrugator supercilii and/or procerus muscle activity was accepted by the NMPA

Note: * progress after the reporting period

Performance Highlights (2/2)

Internationalization

Collaborated with Syneos Health and initiated Serplulimab injection (PD-1) prelaunch in the U.S .

Controlled subsidiary Sisram established new direct sales team in Dubai and proposed to control the brand and channels PhotonMed through M&A to achieve direct sales of energy-based devices in China in 1Q2023; established new direct sales team in the UK in 2022; the direct sales revenue accounts for 66% of the 2022 revenue

Controlled subsidiary Gland Pharma fully acquired Cenexi and entered into Europe -based CDMO by the end of April 2023

Building localized manufacturing capacities in Africa Côte d'Ivoire

Collaboration

License -out: granted the exclusive development and commercialization rights for rituximab injection in 16 emerging markets in Asia and Africa to Boston Oncology , to further enhance the accessibility

Performance Highlights

Revenue

RMB43,952 million
(+12.66% YoY)

Net profit after one -off loss

RMB3,873 million
(+18.17% YoY)

Revenue from regions and countries outside Chinese Mainland

RMB13,938 million
(+2.49% YoY)

Revenue from new launches in the past few years

30%
(>25% in 2021)

Net operating cash flow

RMB4,218 million
(+7.10% YoY)

MSCI-ESG

A

1Q23 Financial Review

Key Financials (RMB million)	1Q23	1Q22*	YoY
Revenue [1]	10,871	10,385	*4.7%*
Net profit attributable to shareholders	987	457	*116.2%*
Net profit after one-off gain/loss [1]	919	801	*14.8%*
Net operating cash flow	873	856	*2.1%*
R&D Expense	969	810	*19.7%*
Basic EPS (RMB/share)	0.37	0.18	*105.6%*

Expense Structure	1Q23	1Q22*
Gross Margin	51.3%	43.6%
Selling and Distribution	23.1%	19.9%
Administrative	9.1%	7.6%
R&D	8.9%	7.8%
Finance	2.4%	1.0%
Gross Margin minus Selling and Distribution	28.2%	23.6%

Key Indicator s	1Q23	2022
Cash and bank balances (RMB million)	15,473	16,241
Net asset attributable to shareholders (RMB million)	45,393	44,582
Current ratio	1.08	1.06
Quick ratio	0.85	

Note 1: the increase of revenue and net profit after one-off loss was caused by the combined impact of: 1) improved product portfolio and increased sales from new launches in the past few years including Serplulimab Injection (PD-1), Trastuzumab Injection(HER2), Avatrombopag Maleate and Azvudine; 2) decreased overseas sales of third party personal protective products for COVID-19; 3) decreased sales of Comirnaty (mRNA COVID-19 vaccine)

Note 2: nonrecurring gain RMB68 million (+RMB412 million YoY), mainly due to market fluctuations of BNTX and other stocks held by the Group results approximately RMB344 million one-off loss in 2022Q1(Fosun Pharma sold all BNTX stake by the end of 2022)

Note 3: the increase of gross margin minus selling and distribution was mainly due to: 1) improved product portfolio and increased sales from new launches in the past few years; 2) the decreased overseas sales of third party personal protective products for COVID-19 with lower gross margins

Note 4: Due to the business consolidations for enterprises under common control in 2022, the Group made retrospective adjustments to the comparative financial information in accordance with the PRC Accounting Standards for Business Enterprises.

2022 Financial Review

Key Financials (RMB million)	2022	2021	YoY
Revenue	43,952	39,011	*12.7%*
Net profit attributable to shareholders	3,731	4,729	*-21.1%*
Net profit after one-off gain/loss	3,873	3,277	*18.2%*
Net operating cash flow	4,218	3,938	*7.1%*
R&D Expenditure	5,885	4,978	*18.2%*
R&D Expense	4,302	3,837	*12.1%*
Basic EPS (RMB/share)	1.43	1.85	*-22.7%*
Dividend Payout Ratio (Subject to approval by the shareholders)	30%	30%	-

Note: nonrecurring loss RMB142 million (-RMB1,593 million YoY), mainly due to market fluctuations of BNTX and other stocks held by the Group; the net effect of BNTX disposal and fair value changes results approximately RMB1 billion one-off loss; realized RMB3,731 million (-21.10% YoY) net profit attributable to shareholders in 2022

Expense Structure	2022	2021
Gross Margin	47.3%	48.1%
Selling and Distribution	20.9%	23.3%
Administrative	8.7%	8.3%
R&D	9.8%	9.8%
Finance	1.5%	1.2%
Gross Margin minus Selling and Distribution	26.4%	24.8%

Note :

The decrease of Gross Margin was mainly due to: 1) the lower gross margins on overseas sales of third party personal protective products for COVID-19; 2) the unit price increase of some core products due to the increase in labor costs and raw materials; 3) but the GM of Pharma business increased by 2.96 pct due to the continuous optimized product structure

The decrease of selling and distribution rate was caused by the combined impact of: 1) continuously strengthen the control of sales expanse; 2) the decreased selling and distribution rate of volume based purchasing products;3) spend on market development and sales team for new launches in the past few years including Serplulimab injection (PD-1)

Key Indicator s	2022	2021
Cash and bank balances (RMB million)	16,241	10,317
Net asset attributable to shareholders (RMB million)	44,582	39,196
Current ratio	1.06	1.04
Quick ratio	0.85	0.85
Debt-to-asset ratio	49.5%	48.2%

Note : the increase of cash and bank balances was mainly due to the raised RMB4.48 billion from non-public placement of A-Shares in July 2022. The raised fund is for 1) innovative drug clinical trials, license-in and launch; 2) construction manufacturing base for API and formulation; 3) replenishment working capital

Strengths and Key Growth Drivers

Strengths


Lean Management System
Corporate Governance
DRG/DIP ongoing payment reform
Import Substitution of IVDs and Medical Devices
Launch innovative product abroad

Access to Opportunities Through In-house R&D, Incubation, Strategic M&A and Collaboration

In-house R&D & Incubation

Investment & M&A

In a constantly evolving industry , Fosun Pharma has accomplished dozens of M&A and license-in agreements by leveraging forward -looking insights

Fosun Pharma will continuously capture development opportunities in the industry and access innovative therapeutic areas, products, and technologies to achieve sustainable organic growth



Lean Management System



Integrating API and formulation manufacturing and focusing on key pipelines

Building a regionalized manufacturing center around Xuzhou Area, vertically integrating Sino API facility with Xuzhou formulation facility to achieve intensive production capacity, covering multiple dosages and disease areas

Chongqing facility and Changde facility have completed the first stage construction; Sino API facility and Xuzhou formulation facility have completed the tech transfer and validation for the first batch. The increased capacity will support future commercial manufacturing

Global Operation (1/2)



Figure number: GS(2016)1666

Global Operation (2/2)



Leveraging global resources, quickly realizing and maximizing product value

Corporate Governance Sustainable Development

MSCI-ESG Rating Upgrade



- Upgraded MSCI ESG rating to A in October 2022, leading the industry
- Topped in the first Fortune China ESG Impact List in August 2022
- Included in the HSCASUS and HSMHSUS

E nvironment

Green growth and sustainable development

- Established EHS Committee to continuously improve EHS policies and set the 2nd EHS five-year strategic goals (2021-2026)
- Invested RMB1.15 million in special fund for water conservation in 2022, with a total annual water saving of 337,806 , 3.2% of the total annual water consumption

S ocial

Improvement of product accessibility and affordability, taken the interest of stakeholders into consideration

- Well-established systems for R&D, product quality management, staff training, social welfare and supply chain management
- Launched 2 orphan drugs/drugs for rare diseases, Aminohexanoic acid powder and Avatrobopag tablet; increased the accessibility of Ejilunsai injection (CAR-T) through commercial insurances and citizen insurances; in-house developed Antimalarial Series including Artesunate saved more than 56 million patients with severe malaria

G overnance

Strengthen corporate governance with ESG to achieve sustainable development

- Established ESG Committee at the Board level; the independent Anti-Corruption Supervision Department (ACSD) designed a comprehensive anti-corruption system
- Published over 10 documents related to corporate governance on the official website
- Upheld the professional, branded, digital and compliant marketing system control

Pharmaceutical

Pharma - Performance

Segment Revenue



Segment Results [1]

Segment Profit [2]

Pharma

3 Divisions

Specialization

Innovative Medicines

Integrated management of innovative drug development by Global R&D Center

Core platforms including small molecule, antibody/ADC, cell therapy and RNA

Established Medicines Manufacturing & Supply

Continuously integrating manufacturing lines to maximize cost advantages

Accelerating the in-house R&D of First-to-market, First three-to-market and complex formulation to commercialize globally

Vaccine

Vaccine Division in early 2022, with R&D and manufacturing capabilities in multivalent conjugate technology, insect cells with recombinant baculovirus technology and inactivated technology

Note 1: segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses
Note 2: pharmaceutical profit excludes the effect on sales of BNTX shares

Pharma - Core Product Revenue in Different Therapeutic Areas in 2022

Anti -tumor and Immune Modulation

RMB5,522 million 26%*
+39.44% YoY

Revenue increase from Trastuzumab Injection (HER2), Avatrombopagmaleate Tablets, Adalimumab injection and from new launches in the past few years including Serplulimab Injection (PD-1) and Netupitant-Palonosetron

Anti -infection

RMB8,582 million 40%*
-0.45% YoY

Mainly due to the combined effect of the decrease in the sales volume of Comirnaty (mRNA COVID-19 vaccine) and Micafungin, the revenue contribution from new products Azvudine tablets, Cravit (levofloxacin tablets and levofloxacin injection)

Metabolism and Alimentary System

RMB2,883 million 13%*
-0.24% YoY

Mainly due to the impact of the execution of centralized procurement for Thioctic acid injection and Glutathione for injection

Cardiovascular System

RMB2,115 million 10%*
+6.12% YoY

Mainly due to the increase in the sales volume of heparin series preparations

Central Nervous System

RMB1,003 million 5%*
-11.79% YoY

Mainly due to the decline in sales volume of deproteinised calf blood serum injection

APIs and Intermediate Products

RMB1,248 million 6%*
+9.96% YoY

Mainly due to the increase in the sales volume of amino acid series

Note: represents core product revenue in single therapeutic area / sum of core product revenue in all therapeutic areas

R&D expenditure drives product portfolio optimization

Phama R&D expenditure was RMB5,097 million (+13.62% YoY) in 2022, accounts for over 85% of the total R&D expenditure and 16.47% of the pharma revenue; Pharma R&D expense was RMB3,552 million, accounts for 11.53% of the pharma revenue

new launches in the past few years including Serplulimab injection (PD-1), Trastuzumab injection (HER2), Avatrombopag tablets and Azvudine tablets accounts for over 30% of the pharma revenue, optimizing product portfolio

Over 260 pipeline drugs in innovative drugs, biosimilars, generic drugs, consistency evaluation items, etc. by the end of 2022; received 249 applied pharma patents, including 16 U.S. patent applications, 17 PCT applications and 48 licensed invention patents in 2022



Pharma Key Progress - Serplulimab Injection

Pharma Key Progress In-house R&D Vaccine Platform

Established Vaccine Subdivision in early 2022, with multivalent conjugate technology, insect cells with recombinant baculovirus technology and inactivated technology, to R&D and manufacture vaccines

Multivalent Conjugate Vaccine

Key progress

Completed the enrollment of the Ph3 clinical trial of 13-valent pneumococcal conjugate vaccines (multivalent combinations) in Chinese Mainland in April 2023

Fosun Adgenvax received Drug Manufacturing License from Sichuan Medical Products Administration in January 2023, laying the foundation for commercial manufacturing of vaccines under development

Received National Intellectual Property Rights

The only multivalent combination technology with national patent and independent intellectual property rights

13-Valent Pneumococcal Conjugate Vaccine is the only pneumonia vaccine listed as a national major project



Structural Design Advantages

Stable antigen structure, rapid immune response, earlier protection, complex antigen structure to enhance immunogenicity and reduce interference with different types of antigen immune response



Cost and Safety Advantages

Meat-free medium for carrier protein to reduce manufacturing cost and period

28 Patents

10+ R&D Projects

40+ R&D Employees

Inactivated Technology

Launched Human Rabies Vaccine (Vero Cells) and Influenza Vaccine

Nearly 20 years experiences in stable commercial manufacturing; innovative technology center for inactivated vaccines in Liaoning Province

Insect Cells with Recombinant Baculovirus Technology

First approved Hi5 insect cell line without nodavirus and SF9 insect cell line without rhabdoviruses in Chinese Mainland

Note: 13-valent pneumococcal conjugate vaccine is used for active immunization of people over 2 months of age against pneumococcal disease caused by type 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F strains of infection. 13-valent pneumococcal conjugate vaccine is in Phase 3 clinical trial in Chinese Mainland

Pharma - Global Commercialization System



2022 Main Progress

Revenue	#	
	5	mRNA COVID-19 vaccine Trastuzumab injection(HER2) Rituximab injection (CD20) Azvudine Heparin series preparations
RMB500-	3	Avatrombopag Maleate Antimalarial series Febuxostat tablets
RMB300-5	8	8 products including Serplulimab injection (PD-1) Glutathione tablets Non-freeze dried human rabies vaccine (VERO cell) Quetiapine fumarate tablets New compound aloe capsules
RMB100-3	31	31 products including Adalimumab injection (TNF-) Escitalopram oxalate tablets Alfacalcidol tablets Pitavastatin calcium tablets

Med Tech - Performance

Segment Revenue



Segment Results [1]



Segment Profit



Medical Devices

Aesthetic Field

As the core medical aesthetic platform, Sisram business covers energy based medical aesthetic devices, injectables, home use devices, aesthetic dentistry

Soprano Hair Removal

Harmony

ThermoLift Skin firming & lifting

LMNT one Home use device

Profhilo Injectable hyaluronic acid treatment

Respiratory Care

Exploiting home/hospital used respiratory devices market through Breas


Z1 CPAP machines

Vivo 45 non-invasive ventilation

Professional Medical Device & Consumables

Including Da Vinci surgical robotic system , negative pressure ambulances, portable CT, etc.

Da Vinci Surgical System

Fosun Diagnosis

Actively integrating the operation; business covering immunodiagnosis, biochemical diagnosis, microbial diagnosis, molecular diagnosis, POCT, etc.

Improving R&D and manufacturing capabilities of diagnostic API, reagents and instruments to provide comprehensive solutions to clients

F-C800p Automatic Biochemical Analyzer

F-i3000 Automated Chemiluminescence Immunoassay Analyzer

Molecular POCT

Note 1: Segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses
Note 2: Segment results increased by 11.87% YoY, segment profit increased by 2.33% YoY, excluding the impact from equity transfer of Yaneng Bioscience


(USD million)
20.5% YoY
354.5
294.3
23.2
32.5
40.1
Revenue
Profit

Medical Devices - Intuitive Fosun

Localization Process

2017 Announced to form a JV with Intuitive Surgical in China in 2016 based on the long-term partnership and established Intuitive Fosun in Shanghai in 2017

2019 Marketing the 4th generation Da Vinci XI Surgical System

2020 Da Vinci Surgical System test drives in more than 10 cities across China, with more than 800 doctors from nearly 200 hospitals participated in the experience

2021 Da Vinci Innovation Center opened with 1,700 m^2 of space to provide high-quality hands-on precision medicine training to approximately 4,000 doctors per year

2022 Building da Vinci Surgical Manufacturing R&D Center in Shanghai, covering about 31.2 acres

Future Localization in technology, manufacturing and services

Made in China
Joint R&D
Global Commercialization

Main Products

Da Vinci Surgical System

55 da Vinci Surgical Systems were installed in China in 2022. By the end of 2022, over 300 Systems were installed in Chinese Mainland, Hong Kong and Macau regions and completed more than 100,000 surgeries within 2022

As of June 30th 2022, 7,544 systems were installed worldwide, with more than 55,000 doctors trained to use the system, and performed over 10 million surgeries .

Ion Endoluminal System

The robotic-assisted bronchoscopy platform, Ion, was approved by FDA in 2019

The Ion guided lung nodule biopsy clinical feasibility trial completed enrollment at Shanghai Chest Hospital in October 2021. It is the first clinical trial using Ion outside the United States

Medical Diagnosis - Core Products

Medical Diagnosis 2022 Major Progress

Promoting the integration of medical diagnosis segment, constructing 6 R&D and manufacturing bases; R&D personnel account for more than 15% of the total number of Medical Diagnosis employees

F-C800p Automatic Biochemical Analyzer launched in June 2022, together with the F-i3000 Automated Chemiluminescence Immunoassay Analyzer, formed Fosun Diagnostics biochemical immunoassay pipeline to meet the clinical diagnostic testing needs

Self-developed COVID-19 Rapid Antigen Test was approved by NMPA in April 2022. It has received EU CE certification and has been included in the EU Common list of COVID-19 antigen tests and completed BfArM registration in Germany

Self-developed Monkeypox PCR Detection Kit received EU CE certification in May 2022

6 R&D and Manufacturing Bases



Healthcare Services

Healthcare Service - Performance

Segment Revenue

(RMB million)



Investment
2011-2017

Segment Results [1]

(RMB million)



Segment Profit

(RMB million)



Healthcare Services - Offline Services

Highlights

Covered Region

Focus on the Yangtze River Delta, the Greater Bay Area and other regions; connecting medical centers with regional medical associations; integrating hospital resources

6,333 beds [1] in hospitals controlled by the Group by the end of 2022

Competitiveness

Foshan Chancheng Hospital received JCI certification and ranked the TOP1 non-public hospital in China for 5 consecutive years [2]

Shenzhen Hengsheng Hospital was granted JVF license

Major Hospitals

Pearl River Delta

Regional flagship hospitals include Foshan Chancheng, Shenzhen Hengsheng, etc.

Class III General Hospital with 1,750 beds

Realized revenue of RMB2,145 million , and profit of RMB111 million in 2022

Fosun Pharma currently holds 86.47% of the share

宿迁市钟吾医院 SUQIAN ZHONGWU HOSPITAL
宿迁市肿瘤医院 SUQIAN CANCER HOSPITAL

卓尔芸 JOYFUL WAY

温州老年病医院 WENZHOU GERIATRIC HOSPITAL

Note1: Last update in December 2022
Note2: According to Ailibi ranking

Healthcare Services Integrating Online and Offline Services

Integrated online and offline healthcare services from 2021, has received 10 internet hospital licenses as for now

Building online medical service platform to provide healthcare services, pharmaceutical and med tech e-commerce , health insurance service and health management services

Accelerating online and offline services integration
Building a one -stop healthcare management FHMO

Online Platform

- Supply Chain: medicine, vaccine, rehab products
- Consultation: specialized doctors
- Integrated with Offline Platform : testing, accompanied consultation
- Content: authority, timeliness

Upstream: Pharmaceutical Supply



Downstream: Insurance Payment

Offline Medical Institutions

- Integrated supply chain
- Integrated with Online Platform: gathering specialists
- Iteration of testing/rehab products
- Network of Medical institutions in Tier 1&2 cities

Sinopharm Performance

Revenue	Profit Attributable	Profit Attributable to Fosun Pharma



Actively complied with the industry transformation trend, strengthened service capability of distribution network, and ensured the steady growth of key regions and markets while continuously improving the coverage and penetration ratio of business network. The 2022 revenue from the pharmaceutical distribution segment reached RMB406.60 billion (+4.27% YoY)

guarding personal protective products for COVID-19, and further enhanced the market share. The 2022 revenue from the medical device segment amounted to RMB120.85 billion (+11.77% YoY)

Actively responded to the national strategy, undertook the new transformation and demand of separation of medical services and pharmaceutical sales, increased the allocation of resources, and made great efforts to promote the balanced development of professional pharmacies and traditional pharmacies. The 2022 revenue from retail pharmacy business reached RMB33.0 billion (+13.49% YoY)

Appendix

Large Molecules Pipeline (1/2)

Therapeutic Area	Product				

Large Molecules Pipeline (2/2)

Therapeutic Area	Product	Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Anti-tumor	FS-1502	HER2	HER2-positive advanced malignant solid tumor						
			HER2-positive locally advanced or metastatic breast cancer						
	FS-1502+Serplulimab	HER2+PD-1	Advanced gastric cancer with HER2 expression						
	HLX14 (Denosumab)[1]	RANKL	Osteoporosis	Initiated Ph3 clinical trial in Chinese Mainland in June 2022; approved to enter Ph3 clinical trial by TGA in July 2022					
	HLX26	LAG-3	Solid tumors and lymphomas						
	HLX35[2]	EGFR 4-1BB	Solid tumors	Approved to enter clinical trials by NMPA in January 2022; first subject had been dosed in Chinese Mainland in June 2022					
	HLX301	PD-L1 TIGIT	Solid tumors	First subject had been dosed in Australia in February 2022; Approved to enter clinical trials by NMPA in March 2022; first subject had been dosed in Chinese Mainland in July 2022					
	HLX15 (Daratumumab)	CD38	Multiple myeloma	First subject had been dosed in Chinese Mainland in February 2023					
	HLX13 (Ipilimumab)	CTLA-4	Melanoma, renal cell carcinoma and metastatic colorectal cancer						
Blood system	Recombinant Human Erythropoietin Injection (pre-filled syringe)	EPO	Anemia of renal disease						
Metabolism and Digestive System	Recombinant Insulin Glargine Injection	INSR	Diabetes						
	Mixed Protamine Zinc Recombinant Insulin Lispro Injection (50R)	INSR	Diabetes						
	Liraglutide Injection	GLP-1	Diabetes						
Others	RT002	Bio 1	Moderate to severe glabellar lines in adults (GL)	The NDA was accepted by the NMPA in April 2023					
		Bio 1	Cervical dystonia (CD)	Completed the enrollment of subjects in Chinese Mainland in January 2022					

Note 1: granted Organon exclusive global commercialization rights except for China

Note 2: granted Binacea to research, develop, manufacture and commercialize the HLX35 globally except for China (including Hong Kong, Macau and Taiwan region)

Note 3: last update on 28th April 2023

Small Molecules Pipeline (1/2)

Therapeutic Area	Project	Target/MOA	Indication	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Anti-tumor	FCN-437c	CDK4/6	Breast cancer (1L)	Approved to enter Ph3 clinical trial by NMPA in January 2022; Ph1 clinical trial in the U.S.					
			Breast cancer (2L)	Approved to enter Ph3 clinical trial by NMPA in January 2022; approved to enter clinical trials by FDA					
	SAF-189	ALK	Non-small cell lung cancer	Initiated Ph3 clinical trial in Chinese Mainland in January 2022; Ph1 clinical trial in the U.S.					
		ROS1	Non-small cell lung cancer	Approved to enter clinical trials by FDA					
	HLX-208	BRAF V600E	Solid tumors (metastatic colorectal cancer, non-small cell lung cancer, etc.) LCH and ECD5	Granted with the Breakthrough Therapy Designation by the NMPA in April 2023 Approved to enter Ph1b/Ph2 clinical trials by NMPA in January 2022					
	FCN-159	MEK	Neurofibromatosis type 1	Global multi-center clinical trial					
			Low-grade glioma						
			Arteriovenous malformation	Approved to enter clinical trials by NMPA in May 2022					
			Histiocytic tumor	Granted with the Breakthrough Therapy Designation by the NMPA in April 2023; Approved to enter clinical trials by NMPA in May 2022					
			Langerhans cell histiocytosis	Approved to enter Ph2 clinical trial by NMPA in March 2023					
			Langerhans cell histiocytosis in children	Approved to enter Ph2 clinical trial by NMPA in March 2023					
	YP01001	VEGFR	Advanced solid tumor						
	FCN-338	BCL-2	Myeloid malignancy	Approved to enter Ph2 clinical trials by NMPA in March 2023					
			Hematological malignancy	Approved to enter Ph1 clinical trial in the U.S.					
			Relapsed or refractory B-cell lymphoma						
	FH-2001	FGFR/PD-L1	Advanced malignant solid tumors						

Note: last update on 28th April 2023

Small Molecules Pipeline (2/2)

Therapeutic Area	Project	Target/MOA	Indication	Pre-Clinical / IND / Phase 1 / Phase 2 / Phase 3 / NDA
Blood System	Avatrombopag Tablet	TPO-R	Chronic idiopathic thrombocytopenic purpura	NDA was accepted by NMPA in December 2022
	Tenapanor Tablet	NHE 3	End-stage Renal Disease Hemodialysis	
Metabolism and Digestive System	Ferric Pyrophosphate Citrate	-	Iron replacement for HD patients	
	Tenapanor Tablet	NHE 3	Irritable Bowel Syndrome with Constipation	Ph1 clinical trial in Chinese Mainland; NDA in Hong Kong and Macau regions
	FCN-342	URAT1	Gout	
Infectious Diseases	Molnupiravir	RNA polymerase	Treatment of COVID-19	
	Paxlovid	3CL Protease	Treatment of COVID-19	
	mRNA COVID-19 BNT162b2 & bivalent vaccine	-	Immunization to prevent COVID-19	Administrated in Hong Kong, Macau and Taiwan regions
	PA-824	-	XDR Tuberculosis MDR Tuberculosis	Launched Pretomanid in the U.S.*
Nervous System	Opicapone Tablet	COMT	Parkinson's syndromes	Launched Ongentys in Europe*
Others	Fortacin spray (Lidocaine Prilocaine spray)	-	Premature ejaculation	Launched in Europe*
	ET-26	-	Anesthesia	Approved to enter Ph2 clinical trial by NMPA in July 2022

Note: last update on 28th April 2023

Vaccine Pipeline

Product	Technology	Pre-Clinical	IND	Phase 1	Phase 2	Phase 3	NDA
Freeze-dried Human Rabies Vaccine (Vero Cells)	Inactivated						
4-Valent Influenza Vaccine	Inactivated						
Human Diploid Cell Rabies Vaccine	Inactivated						
13-Valent Pneumococcal Conjugate Vaccine	Multivalent Conjugate						
24-Valent Pneumococcal Conjugate Vaccine	Multivalent Conjugate						
23-Valent Pneumococcal Conjugate Vaccine	Multivalent Conjugate						
Quadrivalent Meningococcal Polysaccharide Vaccine	Multivalent Conjugate						
Tetanus Vaccine	-						
Quadravalent Meningococcal Conjugate Vaccine	Multivalent Conjugate						
Recombinant Zoster Vaccine	Insect Cells with Recombinant Baculovirus						
Recombinant Quadravalent Influenza Vaccine	Insect Cells with Recombinant Baculovirus						

Note: last update on 28th April 2023

LOGO

Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and Fosun , are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.

FOSUN PHARMA

复星医药

www.fosunpharma.com